Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial

NCT03596450 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

1278

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Semaglutide
DRUG: Standard of care

Sponsor

Novo Nordisk A/S